TransMolecular
From Wikipedia, the free encyclopedia
| Industry | Biotech |
|---|---|
| Headquarters | |
| Parent | Morphotek, Inc. (from 2011) |
| Website | transmolecular |
TransMolecular was a biotech company located in Birmingham, Alabama. It was geared to finding anti-cancer targeted drugs.[1]
TransMolecular, Inc. engaged in discovering, developing, and commercializing therapies for glioma, metastatic brain tumors, and cancers. It developed TM601, a synthetically-produced polypeptide that was derived from scorpion venom, which is used to specifically target tumors in the treatment of cancer.[2] The company was founded in 1996. In 2003, Fortune Magazine listed the company as one of the 14 "most exciting, innovative companies in the nation".[3][4]
In March 2011, TransMolecular's assets were purchased by Morphotek, a subsidiary of the Japanese pharmaceutical company Eisai.[5]
